Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivekimab Sunirine in Pediatric Relapsed or Refractory Acute Myeloid Leukemia
NCT07306832Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 7
01
Overview
Phase 1, open-label trial of pivekimab sunirine in acute myeloid leukemia (AML) (3 cohorts), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Leading to Treatment Discontinuation at 24 months, Maximum Observed Serum/Plasma Concentration (Cmax) of Intact Antibody-Drug Conjugate (ADC) at 22 months and 5 more. Started May 2026; status: recruiting.
02
Drugs
pivekimab sunirine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07306832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07306832.